文献速递治疗药物监测与药物基因组学

药物基因组学知识证据分级框架

An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.
PubMed 文献 · Clin Pharmacol Ther · 2021-07-22

PharmGKB 的临床注释汇总变异-药物关联并赋予证据等级(LOE),随着证据累积,人工维持 LOE 一致性愈发困难。为此作者开发了一套评分系统,按研究规模、报告 P 值、关联支持与否以及指南和 FDA 标签中的变异特异性用药指导等属性对变异注释评分并求和,用于自动计算临床注释的 LOE,提升透明度、一致性与可重复性。

要点

  • 评分系统将变异注释按研究规模、P 值、关联方向及指南/FDA 标签指导等属性计分,汇总后自动赋 LOE。
  • 自动评分旨在提升临床注释 LOE 判定的透明度、一致性与可重复性。
  • 评分系统配合临床注释书写标准化,可维持 PharmGKB 临床注释作为药物基因组学信息的可靠来源。

核心结论

  • 基于属性评分的系统可自动为 PharmGKB 临床注释赋证据等级,提升透明度、一致性与可重复性。

研究设计与样本

  • 方法学描述:PharmGKB 将药物基因组学文献整理为变异注释,变异注释可创建新临床注释或补充已有临床注释。
  • 作者开发评分系统,对变异注释按特定属性评分,并将同一临床注释下所有注释得分求和以计算 LOE。

主要发现

  • 评分属性包括研究规模、报告的 P 值,以及变异注释是否支持或未能发现关联。
  • 给出变异特异性用药指导的临床指南或 FDA 批准药品标签也纳入评分。
  • 同一临床注释可由多名策展人随时间共同维护,证据增多使人工维持 LOE 一致性愈发困难。

关键数值与推荐

  • 变异注释按研究规模、报告的 P 值、关联支持或未发现关联等属性评分。
  • 临床指南或 FDA 批准药品标签若给出变异特异性用药指导也纳入评分。
  • 临床注释下所有注释得分求和得到总分,用于计算 LOE。

临床怎么用

  • 临床药学智能体可参考该框架理解 PharmGKB 临床注释 LOE 的生成逻辑与证据权重。
  • 解读变异-药物关联时应关注研究规模、P 值及是否有指南或 FDA 标签的变异特异性用药指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical annotations are one of the most popular resources available on the Pharmacogenomics Knowledgebase (PharmGKB). Each clinical annotation summarizes the association between variant-drug pairs, shows relevant findings from the curated literature, and is assigned a level of evidence (LOE) to indicate the strength of support for that association. Evidence from the pharmacogenomic literature is curated into PharmGKB as variant annotations, which can be used to create new clinical annotations or added to existing clinical annotations. This means that the same clinical annotation can be worked on by multiple curators over time. As more evidence is curated into PharmGKB, the task of maintaining consistency when assessing all the available evidence and assigning an LOE becomes increasingly difficult. To remedy this, a scoring system has been developed to automate LOE assignment to clinical annotations. Variant annotations are scored according to certain attributes, including study size, reported P value, and whether the variant annotation supports or fails to find an association. Clinical guidelines or US Food and Drug Administration (FDA)-approved drug labels which give variant-specific prescribing guidance are also scored. The scores of all annotations attached to a clinical annotation are summed together to give a total score for the clinical annotation, which is used to calculate an LOE. Overall, the system increases transparency, consistency, and reproducibility in LOE assignment to clinical annotations. In combination with increased standardization of how clinical annotations are written, use of this scoring system helps to ensure that PharmGKB clinical annotations continue to be a robust source of pharmacogenomic information.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Whirl-Carrillo M, Huddart R, Gong L, et al. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021. PMID: 34216021. doi:10.1002/cpt.2350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。